Stable producer cell lines helped to make mAb therapies the powerhouses they are today. To deliver on the promise of AAV-based gene therapy for prevalent diseases, we need similar technology. The challenge is that multiple genetic elements – rep, helper, capsid, and gene of interest – must be present. Ideally, everything needed to produce the required rAAV would be stably integrated in a single cell line. We describe such an all-inclusive cell line platform that can be customized for your specific GOI and capsid. Just add the induction agent, and you’re ready to go.
In this webinar:
- Discover the drawbacks of using a cell line that’s not complete
- See how to use the ELEVECTA™ platform to produce high-quality AAV at high yield for indications with large patient populations
- Take a deep dive into data on robust scaling to large-scale stirred tank bioreactors
- Learn how Cytiva can help you optimize your upstream processing — with cells, media, bioreactors, and filters that work in tandem
